title: Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement.
abstract: The clinical, surgical, and histopathologic data from 202 patients with endometrial adenocarcinoma with cervical involvement are presented. One hundred fifty-one (75%) had histopathologically confirmed cervical involvement at the time of their definitive surgery, while in 51 (25%) no cervical involvement was conclusively identified. The 5-year actuarial survival for patients with true surgical stage II endometrial carcinoma (N = 24) was 76%. Extrauterine disease was documented in 32% (27/84) of patients in which the primary treatment modality was surgical. The 5-year actuarial survival was 65% for all patients with clinical surgical stage II disease. There appeared to be a survival advantage for patients treated by radical surgery as compared with more conventional treatments, especially in patients with numerous high-risk factors. The subgroup of patients (N = 53) having tumor grossly involving the cervix had a 5-year survival of 48%. In this subgroup of patients, radical hysterectomy offered improved 5-year survival over more traditional forms of treatment, particularly compared with simple hysterectomy or combined treatment with radiation and surgery. Multivariate analysis positively correlated myometrial invasion, grade, uterine serosal involvement, lower uterine segment involvement, adnexal metastasis, pelvic metastasis, aortic node metastasis, and peritoneal cytology, with disease-free survival. Clinical and surgical findings correlated poorly; therefore, primary surgical evaluation is recommended when possible.
authors.affiliation: Section of Gynecologic Oncology, Rush Presbyterian St. Luke's Hospital, Chicago, Illinois.
authors.forename: M P
authors.initials: MP
authors.lastname: Boente
authors.forename: E L
authors.initials: EL
authors.lastname: Yordan
authors.forename: D G
authors.initials: DG
authors.lastname: McIntosh
authors.forename: E C
authors.initials: EC
authors.lastname: Grendys
authors.forename: Y A
authors.initials: YA
authors.lastname: Orandi
authors.forename: S
authors.initials: S
authors.lastname: Davies
authors.forename: D
authors.initials: D
authors.lastname: Beck
authors.forename: J E
authors.initials: JE
authors.lastname: Graham
authors.forename: A
authors.initials: A
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Marshall
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D015993:Life Tables; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy